Autopsy report · NCT05135650

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

“Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year before it stopped.
• 20 participants enrolled.
• Results were posted on the registry 2 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Fred Hutchinson Cancer Center

Sponsor type

University, hospital or other

Conditions

COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Interventions

Questionnaire Administration; Sotrovimab; Biospecimen Collection

Participants

20

Sites

1

Countries

United States

Trials that died the same way

• Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
  “Terminated after FDA agreement.” (64% match in meaning)
• At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
  “In April 2021 FDA revoked the Emergency Use Authorization after determining that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use.” (62% match in meaning)
• A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
  “The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been approved).The sponsor terminated the trial.” (60% match in meaning)
• Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma
  “Terminated 4/17/07. Drug sponsor withdrew.” (58% match in meaning)
• A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
  “Administratively terminated per FDA recommendation” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.